Those are some of the practice-changing conclusions of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1102 study of older patients with high-risk MDS. Our panel of experts will delve into the implications for your practice during a 60-minute roundtable webinar on Thursday, March 17, at 11:30 a.m. CDT.
You'll walk away from the webinar with a better understanding of:
• The BMT CTN 1102 study—a multicenter, biologic assignment trial in older patients with high-risk MDS to define the benefit of hematopoietic cell transplant (HCT) over non-HCT therapy
• How quality of life and functional performance status are better than age in determining eligibility for HCT
• How advances in HCT facilitate improved survival and preserve quality of life
• What these findings mean for community hematologists/oncologists who see patients with MDS
• Best practices for referring patients to a transplant center early for HCT consultation
The Medical College of Wisconsin designates this Virtual Activity for a maximum of 1 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.